Kymab Series C round brings in £81mm
Executive Summary
Kymab Ltd. (transgenic human antibody development platform) raised £81mm ($100.5mm) in its Series C round led by new investor ORI Healthcare Fund. New backer Shenzhen Hepalink Pharmaceutical also participated along with returning shareholders Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corp., CF Woodford Equity Income Fund, and Woodford Patient Capital. Kymab expects one of its therapeutic antibody programs to enter the clinic in 2017; proceeds from this financing will fund development of that and other candidates in the company’s pipeline.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice